4//SEC Filing
Pivotal bioVenture Partners Fund I, L.P. 4
Accession 0001012975-25-000730
CIK 0002044725other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:46 PM ET
Size
35.8 KB
Accession
0001012975-25-000730
Insider Transaction Report
Form 4
Evommune, Inc.EVMN
Pivotal bioVenture Partners Fund I, L.P.
Director10% Owner
Transactions
- Conversion
Series Seed Preferred Stock
2025-11-07−7,145,647→ 0 total(indirect: See footnotes)→ Common Stock (838,886 underlying) - Conversion
Series Seed Preferred Stock
2025-11-07−3,572,816→ 0 total(indirect: See footnotes)→ Common Stock (419,441 underlying) - Conversion
Series A Preferred Stock
2025-11-07−2,582,243→ 0 total(indirect: See footnotes)→ Common Stock (324,578 underlying) - Conversion
Common Stock
2025-11-07+1,441,032→ 1,441,032 total(indirect: See footnotes) - Conversion
Common Stock
2025-11-07+1,632,441→ 1,632,441 total(indirect: See footnotes) - Conversion
Series B Preferred Stock
2025-11-07−1,895,260→ 0 total(indirect: See footnotes)→ Common Stock (240,756 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Series C Preferred Stock
2025-11-07−2,508,575→ 0 total(indirect: See footnotes)→ Common Stock (294,502 underlying) - Conversion
Common Stock
2025-11-07+294,502→ 294,502 total(indirect: See footnotes) - Conversion
Series A Preferred Stock
2025-11-07−7,230,283→ 0 total(indirect: See footnotes)→ Common Stock (908,821 underlying) - Conversion
Series B Preferred Stock
2025-11-07−2,104,740→ 0 total(indirect: See footnotes)→ Common Stock (267,367 underlying)
Pivotal bioVenture Partners Fund I G.P., L.P.
Director10% Owner
Transactions
- Conversion
Series A Preferred Stock
2025-11-07−7,230,283→ 0 total(indirect: See footnotes)→ Common Stock (908,821 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Common Stock
2025-11-07+294,502→ 294,502 total(indirect: See footnotes) - Conversion
Common Stock
2025-11-07+1,441,032→ 1,441,032 total(indirect: See footnotes) - Conversion
Series Seed Preferred Stock
2025-11-07−3,572,816→ 0 total(indirect: See footnotes)→ Common Stock (419,441 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Common Stock
2025-11-07+1,632,441→ 1,632,441 total(indirect: See footnotes) - Conversion
Series Seed Preferred Stock
2025-11-07−7,145,647→ 0 total(indirect: See footnotes)→ Common Stock (838,886 underlying) - Conversion
Series A Preferred Stock
2025-11-07−2,582,243→ 0 total(indirect: See footnotes)→ Common Stock (324,578 underlying) - Conversion
Series B Preferred Stock
2025-11-07−1,895,260→ 0 total(indirect: See footnotes)→ Common Stock (240,756 underlying) - Conversion
Series B Preferred Stock
2025-11-07−2,104,740→ 0 total(indirect: See footnotes)→ Common Stock (267,367 underlying) - Conversion
Series C Preferred Stock
2025-11-07−2,508,575→ 0 total(indirect: See footnotes)→ Common Stock (294,502 underlying)
Pivotal bioVenture Partners Fund I U.G.P. Ltd
Director10% Owner
Transactions
- Conversion
Common Stock
2025-11-07+1,441,032→ 1,441,032 total(indirect: See footnotes) - Conversion
Common Stock
2025-11-07+1,632,441→ 1,632,441 total(indirect: See footnotes) - Conversion
Series Seed Preferred Stock
2025-11-07−7,145,647→ 0 total(indirect: See footnotes)→ Common Stock (838,886 underlying) - Conversion
Series Seed Preferred Stock
2025-11-07−3,572,816→ 0 total(indirect: See footnotes)→ Common Stock (419,441 underlying) - Conversion
Series A Preferred Stock
2025-11-07−7,230,283→ 0 total(indirect: See footnotes)→ Common Stock (908,821 underlying) - Conversion
Series B Preferred Stock
2025-11-07−1,895,260→ 0 total(indirect: See footnotes)→ Common Stock (240,756 underlying) - Conversion
Series B Preferred Stock
2025-11-07−2,104,740→ 0 total(indirect: See footnotes)→ Common Stock (267,367 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Series C Preferred Stock
2025-11-07−2,508,575→ 0 total(indirect: See footnotes)→ Common Stock (294,502 underlying) - Conversion
Series A Preferred Stock
2025-11-07−2,582,243→ 0 total(indirect: See footnotes)→ Common Stock (324,578 underlying) - Conversion
Series C Preferred Stock
2025-11-07−313,571→ 0 total(indirect: See footnotes)→ Common Stock (36,812 underlying) - Conversion
Common Stock
2025-11-07+294,502→ 294,502 total(indirect: See footnotes)
Footnotes (10)
- [F1]Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F10]The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
- [F2]Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
- [F3]Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
- [F4]Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
- [F5]Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").
- [F6]Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").
- [F7]Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").
- [F8]The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.
- [F9]The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
Issuer
Evommune, Inc.
CIK 0002044725
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001695076
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:46 PM ET
- Size
- 35.8 KB